Decreased expression of galectin-3 is associated with progression of human breast cancer

Vincent Castronovo, Frédéric A. Van den Brûle, Pascale Jackers, Nathalie Clausse, Fu-Tong Liu, Claudette Gillet, Mark E. Sobel

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Galectin-3, a member of the β-galactoside-binding lectin family, is involved in several biological events including binding to the basement membrane glycoprotein laminin. Although the exact role of galectin-3 during the interactions between cells and laminin is not yet known, it has recently been observed that its expression is down-regulated at both the protein and the mRNA level in colon cancer tissues in correlation with progression of the disease. This study investigated the possibility that breast cancer cells might also exhibit decreased galectin-3 expression in association with their aggressiveness. The expression of galectin-3 was examined by immunoperoxidase staining, using a polyclonal antibody raised against recombinant galectin-3, in a collection of 98 human breast lesions including 12 fibroadenomas, 15 fibrocystic disease lesions, 22 in situ carcinomas, and 49 infiltrating ductal carcinomas, 19 of which had positive axillary lymph nodes. Normal breast tissue adjacent to the lesions was present in 59 biopsies. Normal breast tissue expressed high levels (3+) of galectin-3. High expression (2+ to 3+) was also found in most benign lesions examined. The expression of galectin-3 was significantly decreased in in situ carcinoma and this down-regulation was more pronounced in invasive ductal carcinoma, particularly when associated with infiltration of axillary lymph nodes. These data constitute the first observation that galectin-3 is down-regulated in breast cancer and suggest the decreased expression of this galactoside-binding lectin is associated with the acquisition of the invasive and metastatic phenotype.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Pathology
Volume179
Issue number1
DOIs
StatePublished - 1996

Fingerprint

Galectin 3
Breast Neoplasms
Galactosides
Ductal Carcinoma
Breast
Carcinoma in Situ
Laminin
Lectins
Lymph Nodes
Fibroadenoma
Membrane Glycoproteins
Basement Membrane
Cell Communication
Colonic Neoplasms
Disease Progression
Down-Regulation
Observation
Staining and Labeling
Phenotype
Biopsy

Keywords

  • Breast cancer
  • Expression
  • Galectin-3
  • Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Castronovo, V., Van den Brûle, F. A., Jackers, P., Clausse, N., Liu, F-T., Gillet, C., & Sobel, M. E. (1996). Decreased expression of galectin-3 is associated with progression of human breast cancer. Journal of Pathology, 179(1), 43-48. https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N

Decreased expression of galectin-3 is associated with progression of human breast cancer. / Castronovo, Vincent; Van den Brûle, Frédéric A.; Jackers, Pascale; Clausse, Nathalie; Liu, Fu-Tong; Gillet, Claudette; Sobel, Mark E.

In: Journal of Pathology, Vol. 179, No. 1, 1996, p. 43-48.

Research output: Contribution to journalArticle

Castronovo, V, Van den Brûle, FA, Jackers, P, Clausse, N, Liu, F-T, Gillet, C & Sobel, ME 1996, 'Decreased expression of galectin-3 is associated with progression of human breast cancer', Journal of Pathology, vol. 179, no. 1, pp. 43-48. https://doi.org/10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N
Castronovo, Vincent ; Van den Brûle, Frédéric A. ; Jackers, Pascale ; Clausse, Nathalie ; Liu, Fu-Tong ; Gillet, Claudette ; Sobel, Mark E. / Decreased expression of galectin-3 is associated with progression of human breast cancer. In: Journal of Pathology. 1996 ; Vol. 179, No. 1. pp. 43-48.
@article{0a38460439a84ce387e19e18ecba9a60,
title = "Decreased expression of galectin-3 is associated with progression of human breast cancer",
abstract = "Galectin-3, a member of the β-galactoside-binding lectin family, is involved in several biological events including binding to the basement membrane glycoprotein laminin. Although the exact role of galectin-3 during the interactions between cells and laminin is not yet known, it has recently been observed that its expression is down-regulated at both the protein and the mRNA level in colon cancer tissues in correlation with progression of the disease. This study investigated the possibility that breast cancer cells might also exhibit decreased galectin-3 expression in association with their aggressiveness. The expression of galectin-3 was examined by immunoperoxidase staining, using a polyclonal antibody raised against recombinant galectin-3, in a collection of 98 human breast lesions including 12 fibroadenomas, 15 fibrocystic disease lesions, 22 in situ carcinomas, and 49 infiltrating ductal carcinomas, 19 of which had positive axillary lymph nodes. Normal breast tissue adjacent to the lesions was present in 59 biopsies. Normal breast tissue expressed high levels (3+) of galectin-3. High expression (2+ to 3+) was also found in most benign lesions examined. The expression of galectin-3 was significantly decreased in in situ carcinoma and this down-regulation was more pronounced in invasive ductal carcinoma, particularly when associated with infiltration of axillary lymph nodes. These data constitute the first observation that galectin-3 is down-regulated in breast cancer and suggest the decreased expression of this galactoside-binding lectin is associated with the acquisition of the invasive and metastatic phenotype.",
keywords = "Breast cancer, Expression, Galectin-3, Immunohistochemistry",
author = "Vincent Castronovo and {Van den Br{\^u}le}, {Fr{\'e}d{\'e}ric A.} and Pascale Jackers and Nathalie Clausse and Fu-Tong Liu and Claudette Gillet and Sobel, {Mark E.}",
year = "1996",
doi = "10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N",
language = "English (US)",
volume = "179",
pages = "43--48",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Decreased expression of galectin-3 is associated with progression of human breast cancer

AU - Castronovo, Vincent

AU - Van den Brûle, Frédéric A.

AU - Jackers, Pascale

AU - Clausse, Nathalie

AU - Liu, Fu-Tong

AU - Gillet, Claudette

AU - Sobel, Mark E.

PY - 1996

Y1 - 1996

N2 - Galectin-3, a member of the β-galactoside-binding lectin family, is involved in several biological events including binding to the basement membrane glycoprotein laminin. Although the exact role of galectin-3 during the interactions between cells and laminin is not yet known, it has recently been observed that its expression is down-regulated at both the protein and the mRNA level in colon cancer tissues in correlation with progression of the disease. This study investigated the possibility that breast cancer cells might also exhibit decreased galectin-3 expression in association with their aggressiveness. The expression of galectin-3 was examined by immunoperoxidase staining, using a polyclonal antibody raised against recombinant galectin-3, in a collection of 98 human breast lesions including 12 fibroadenomas, 15 fibrocystic disease lesions, 22 in situ carcinomas, and 49 infiltrating ductal carcinomas, 19 of which had positive axillary lymph nodes. Normal breast tissue adjacent to the lesions was present in 59 biopsies. Normal breast tissue expressed high levels (3+) of galectin-3. High expression (2+ to 3+) was also found in most benign lesions examined. The expression of galectin-3 was significantly decreased in in situ carcinoma and this down-regulation was more pronounced in invasive ductal carcinoma, particularly when associated with infiltration of axillary lymph nodes. These data constitute the first observation that galectin-3 is down-regulated in breast cancer and suggest the decreased expression of this galactoside-binding lectin is associated with the acquisition of the invasive and metastatic phenotype.

AB - Galectin-3, a member of the β-galactoside-binding lectin family, is involved in several biological events including binding to the basement membrane glycoprotein laminin. Although the exact role of galectin-3 during the interactions between cells and laminin is not yet known, it has recently been observed that its expression is down-regulated at both the protein and the mRNA level in colon cancer tissues in correlation with progression of the disease. This study investigated the possibility that breast cancer cells might also exhibit decreased galectin-3 expression in association with their aggressiveness. The expression of galectin-3 was examined by immunoperoxidase staining, using a polyclonal antibody raised against recombinant galectin-3, in a collection of 98 human breast lesions including 12 fibroadenomas, 15 fibrocystic disease lesions, 22 in situ carcinomas, and 49 infiltrating ductal carcinomas, 19 of which had positive axillary lymph nodes. Normal breast tissue adjacent to the lesions was present in 59 biopsies. Normal breast tissue expressed high levels (3+) of galectin-3. High expression (2+ to 3+) was also found in most benign lesions examined. The expression of galectin-3 was significantly decreased in in situ carcinoma and this down-regulation was more pronounced in invasive ductal carcinoma, particularly when associated with infiltration of axillary lymph nodes. These data constitute the first observation that galectin-3 is down-regulated in breast cancer and suggest the decreased expression of this galactoside-binding lectin is associated with the acquisition of the invasive and metastatic phenotype.

KW - Breast cancer

KW - Expression

KW - Galectin-3

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=0029899818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029899818&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N

DO - 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N

M3 - Article

C2 - 8691344

AN - SCOPUS:0029899818

VL - 179

SP - 43

EP - 48

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 1

ER -